Research ArticleOriginal Article
Open Access

Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention

Seyed Mohammad H. Adel, Fateme Jorfi, Hoda Mombeini, Homeira Rashidi and Saad Fazeli
Saudi Medical Journal May 2022, 43 (5) 458-464; DOI: https://doi.org/10.15537/smj.2022.43.5.20220018

References

  1. 1.↵
    1. Yang Y,
    2. Park G-M,
    3. Han S,
    4. Kim Y-G,
    5. Suh J,
    6. Park HW, et al.
    Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a Korean nationwide study. PLoS ONE 2018; 13: e0208746.
    OpenUrl
  2. 2.↵
    1. Malviya A,
    2. Mishra A.
    Coronary intervention in diabetes: is it different. Heart Asia 2015; 7: 9–14.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Zheng J,
    2. Cheng J,
    3. Zhang Q,
    4. Qi C,
    5. Wang T,
    6. Xiao X.
    Association between glycosylated hemoglobin level and cardiovascular outcomes in diabetic patients after percutaneous coronary intervention. Medicine (Baltimore) 2016; 95: e3696.
    OpenUrl
  4. 4.↵
    1. Park GM,
    2. Lee SW,
    3. Cho YR,
    4. Kim CJ,
    5. Cho JS,
    6. Park MW, et al.
    Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014; 113: 765–771.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Patel A,
    2. MacMahon S,
    3. Chalmers J,
    4. Neal B,
    5. Billot L
    ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Tada T,
    2. Kimura T,
    3. Morimoto T,
    4. Ono K,
    5. Furukawa Y,
    6. Nakagawa Y
    , et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, noninsulin treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 2011; 107: 1155–1162.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Lee TT,
    2. Feinberg L,
    3. Baim DS,
    4. Holmes DR,
    5. Aroesty JM,
    6. Carrozza Jr JP, et al.
    Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol 2006; 98: 718–721.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Aguilar D,
    2. Solomon SD,
    3. Køber L,
    4. Rouleau JL,
    5. Skali H,
    6. McMurray JJV, et al.
    Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction the valsartan in acute myocardial infarction (VALIANT) trial. Circulation 2004; 110: 1572–1578.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kajiwara M,
    2. Tanaka A,
    3. Kawasaki T,
    4. Nakao K,
    5. Sakamoto T,
    6. Toyoda S, et al.
    Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. J Cardiol 2017; 69: 511–517.
    OpenUrl
  10. 10.↵
    1. Corpus RA,
    2. George PB,
    3. House JA,
    4. Dixon SR,
    5. Ajluni SC,
    6. Devlin WH, et al.
    Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8–14.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Sasso FC,
    2. Rinaldi L,
    3. Lascar N,
    4. Marrone A,
    5. Pafundi PC,
    6. Adinolfi LE, et al.
    Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes. J Diabetes Res 2018; 2018: 3106056.
    OpenUrl
  12. 12.
    1. McGuire DK,
    2. Newby LK,
    3. Bhapkar MV,
    4. Moliterno DJ,
    5. Hochman JS,
    6. Klein WW
    , et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246–252.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Deedwania P,
    2. Kosiborod M,
    3. Barrett E,
    4. Ceriello A,
    5. Isley W,
    6. Mazzone T, et al.
    Hyperglycemia and acute coronary syndrome. Circulation 2008; 117: 1610–1619
    OpenUrlAbstract/FREE Full Text
  14. 14.
    1. Duckworth W,
    2. Abraira C,
    3. Moritz T,
    4. Reda D,
    5. Emanuele N,
    6. Reaven PD, et al.
    Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.
    1. Boussageon R,
    2. Bejan-Angoulvant T,
    3. Saadatian-Elahi M,
    4. Lafont S,
    5. Bergeonneau C,
    6. Kassai B, et al.
    Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 2011; 343: d4169.
    OpenUrlAbstract/FREE Full Text
  16. 16.
    1. Hemmingsen B,
    2. Lund SS,
    3. Gluud C,
    4. Vaag A,
    5. Almdal T,
    6. Hemmingsen C, et al.
    Intensive glycemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMJ 2011; 343: d6898.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Fitchett D,
    2. Zinman B,
    3. Wanner C,
    4. Lachin JM,
    5. Hantel S,
    6. Salsali A, et al.
    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016; 37: 1526–1534.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Pham D,
    2. Albuquerque Rocha N,
    3. McGuire DK,
    4. Neeland IJ.
    Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovascular Med 2017; 27: 144–151.
    OpenUrl
  19. 19.↵
    1. Rajasekeran H,
    2. Lytvyn Y,
    3. Cherney DZ.
    Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 2016; 89: 524–526.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Heerspink HJ,
    2. Perkins BA,
    3. Fitchett DH,
    4. Husain M,
    5. Cherney DZ.
    Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752–772.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM,
    4. Fitchett D,
    5. Bluhmki E,
    6. Hantel S, et al.
    Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Verma S,
    2. Mazer CD,
    3. Fitchett D,
    4. Inzucchi SE,
    5. Pfarr E,
    6. George GT, et al.
    Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 2018; 61: 1712–1723.
    OpenUrl
  23. 23.↵
    1. Chang XW,
    2. Zhang SY,
    3. Wang H,
    4. Zhang MM,
    5. Zheng WF,
    6. Ma HF, et al.
    Combined value of red blood cell distribution width and global registry of acute coronary events risk score on predicting long-term major adverse cardiac events in STEMI patients undergoing primary PCI. Oncotarget 2018; 9: 13971–13980.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Verma S,
    2. Mazer CD,
    3. Bhatt DL,
    4. Raj SR,
    5. Yan AT,
    6. Verma A, et al.
    Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: A sub analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2019; 42: e42–e44.
    OpenUrlFREE Full Text
  25. 25.↵
    1. Inzucchi SE,
    2. Khunti K,
    3. Fitchett DH,
    4. Wanner C,
    5. Mattheus M,
    6. George JT,
    7. Ofstad AP,
    8. Zinman B.
    Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. J Clin Endocrinol Metab 2020; 105: 3025–3035
    OpenUrl
  26. 26.↵
    1. Cosentino F,
    2. Grant PJ,
    3. Aboyans V,
    4. Bailey CJ,
    5. Ceriello A,
    6. Delgado V, et al.
    2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Fujita T,
    2. Takeda T,
    3. Tsujino Y,
    4. Yamaji M,
    5. Sakaguchi T,
    6. Maeda K, et al.
    Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia; A serial intravascular ultrasound study. Circulation 1997; 95: 1366–1369.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Iakovou I,
    2. Schmidt T,
    3. Bonizzoni E,
    4. Ge L,
    5. Sangiorgi GM,
    6. Stankovic G
    , et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–2130.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords